The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF)

被引：0
|
作者：
Noble, P. [1 ]
Albera, C. [2 ]
Bradford, W. [3 ]
Costabel, U. [4 ]
Kardatzke, D. [3 ]
King, T., Jr. [5 ]
Sahn, S. [6 ]
Szwarcberg, J. [3 ]
Valeyre, D. [7 ]
du Bois, R. [8 ]
机构：
[1] Duke Univ, Durham, NC USA
[2] Univ Turin, I-10124 Turin, Italy
[3] InterMune Inc, Brisbane, CA USA
[4] Ruhrlandklin, Essen, Germany
[5] UCSF, San Francisco, CA USA
[6] MUSC, Charleston, SC USA
[7] Assistance Publ Hop, Paris, France
[8] Natl Jewish, Denver, CO USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2009年 / 179卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1129
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
    Costabel, Ulrich
    Albera, Carlo
    Wijsenbeek, Marlies S.
    de Andrade, Joao A.
    Mason, Wendi R.
    Nathan, Steven D.
    Zibrak, Joseph D.
    Padilla, Maria L.
    Gilberg, Frank
    Petzinger, Ute
    Kirchgaessler, Klaus-Uwe
    Lancaster, Lisa H.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [2] Double-Blind, Placebo-Controlled, Randomized Trial Of Pirfenidone In Chinese Idiopathic Pulmonary Fibrosis Patients
    Huang, H.
    Xu, Z.
    Kang, J.
    Dai, H.
    Chen, B.
    Sun, T.
    Cao, J.
    Feng, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] The Ascend Study: A Randomized, Double-Blind, Placebo Controlled Trial Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf)
    King, T. E.
    Bradford, W. Z.
    Castro-Bernadini, S.
    Fagan, E. A.
    Glaspole, I.
    Glassberg, M. K.
    Gorina, E.
    Hopkins, P. M.
    Kardatzke, D.
    Lancaster, L.
    Lederer, D. J.
    Nathan, S. D.
    Pereira, C. A.
    Sahn, S. A.
    Sussman, R.
    Swigris, J. J.
    Noble, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [4] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    Azuma, A
    Nukiwa, T
    Tsuboi, E
    Suga, M
    Abe, S
    Nakata, K
    Taguchi, Y
    Nagai, S
    Itoh, H
    Ohi, M
    Sato, A
    Kudoh, S
    Raghu, G
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) : 1040 - 1047
  • [5] Effect Of Treatment With Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf): A Meta-Analysis Of 5 Randomized, Double-Blind, Placebo Controlled Clinical Trials
    Lederer, D. J.
    Albera, C.
    Bradford, W. Z.
    Costabel, U.
    du Bois, R. M.
    Fagan, E. A.
    Fishman, R. S.
    Glaspole, I.
    Glassberg, M. K.
    King, T. E.
    Lancaster, L.
    Leff, J. A.
    Nathan, S. D.
    Pereira, C. A.
    Sahn, S. A.
    Swigris, J. J.
    Valeyre, D.
    Noble, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [6] Analysis Of Pooled Data From 3 Phase 3, Multinational, Randomized, Double-Blind, Placebo Controlled Trials Evaluating Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf)
    Noble, P. W.
    Albera, C.
    Bradford, W. Z.
    Costabel, U.
    du Bois, R. M.
    Fagan, E. A.
    Fishman, R.
    Glaspole, I.
    Glassberg, M. K.
    Lancaster, L.
    Lederer, D. J.
    Leff, J. A.
    Nathan, S. D.
    Pereira, C. A.
    Sahn, S. A.
    Swigris, J. J.
    Valeyre, D.
    King, T. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [7] Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
    Richeldi, Luca
    Azuma, Arata
    Cottin, Vincent
    Kreuter, Michael
    Maher, Toby M.
    Martinez, Fernando J.
    Oldham, Justin M.
    Valenzuela, Claudia
    Gordat, Maud
    Liu, Yi
    Stowasser, Susanne
    Zoz, Donald F.
    Wijsenbeek, Marlies S.
    BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
  • [8] PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS
    KENT, GG
    LANCET, 1980, 1 (8182): : 1363 - 1364
  • [9] Safety and Efficacy of SAR156597 in Idiopathic Pulmonary Fibrosis (IPF): A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Raghu, G.
    Richeldi, L.
    Crestani, B.
    Wung, P.
    Bejuit, R.
    Esperet, C.
    Soubrane, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] The RIFF Study (Cohort B): A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Lebrikizumab in Combination with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Maher, T. M.
    Kondoh, Y.
    Corte, T. J.
    Glassberg, M. K.
    Costabel, U.
    Lancaster, L. H.
    Kardatzke, D.
    Kaminski, J.
    Howard, M.
    Olsson, J. K.
    Neighbors, M.
    Owen, R.
    Belloni, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
12345